Mainz Biomed (NASDAQ:MYNZ) Stock Price Up 2.5%

Mainz Biomed (NASDAQ:MYNZ)’s share price was up 2.5% during trading on Wednesday . The stock traded as high as $2.09 and last traded at $2.06. Approximately 30,015 shares traded hands during trading, a decline of 52% from the average daily volume of 62,648 shares. The stock had previously closed at $2.01.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on MYNZ shares. HC Wainwright raised their price target on Mainz Biomed from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Friday, September 22nd. Cantor Fitzgerald restated an “overweight” rating and set a $9.00 price target on shares of Mainz Biomed in a research note on Tuesday, September 26th.

Mainz Biomed Stock Performance

The firm has a 50 day simple moving average of $2.85 and a 200-day simple moving average of $3.96. The company has a quick ratio of 1.10, a current ratio of 1.13 and a debt-to-equity ratio of 0.30.

Mainz Biomed (NASDAQ:MYNZ) last issued its quarterly earnings results on Tuesday, August 15th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.14). The business had revenue of $0.25 million during the quarter, compared to analyst estimates of $0.25 million. Sell-side analysts predict that Mainz Biomed will post -1.88 EPS for the current fiscal year.

About Mainz Biomed

Mainz Biomed N.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics. It offers ColoAlert, a colorectal cancer screening stool-based deoxyribonucleic acid test; and PancAlert, a product candidate for a pancreatic cancer screening test.